Currently, the laboratory diagnosis of human fascioliasis is based on the parasitological 28 examination of parasite eggs in stool specimens and serological detection of specific 29
INTRODUCTION 53
Fascioliasis is a worldwide zoonotic infection caused by liver flukes of the genus 54 Fasciola, of which F. hepatica and a larger species, F. gigantica are the most common 55
representatives. These two food-borne trematodes usually infect domestic ruminants and 56 causing important economic losses to sheep, goats, and cattle, in commercial herds (1) . 57
Today, fascioliasis is considered an important human disease and several areas e.g. 58 tropical regions of Africa and Asia have been described as endemic for the disease in 59 humans with estimates of 2.4 to 17 million people infected and 91.1 million are at risk 60 worldwide (2, 3). Egypt, especially Nile Delta is a hot spot and Fasciola infection 61 appeared to be endemic with estimated prevalence varying between 2 to 17% (4-6). 62
Furthermore, fascioliasis has been recognized as an emerging infection in international 63 travelers and migrants, causing significant problems in diagnosis and therapy (7). Owing 64 to its high endemicity in some developing countries and emerging nature, the WHO 65 classified the disease as a neglected parasitic infection and decided to launch a 66 worldwide initiative against this infectious disease (2). 67
Diagnosis of human fascioliasis is based on clinical findings and laboratory tests. The 68 most reliable means is the finding of parasite eggs in stool of infected individual (8). 69
However, parasitological diagnosis of human fascioliasis is time-consuming and usually 70 lack sensitivity and reproducibility, and often unreliable because parasite eggs are not 71 found during the prepatent period, approximately 3-4 months after infection (9). homogenized together using two Luer-lock syringes connected to a 3-way stainless steel 158 valve. Each rabbit was immunized subcutaneously three times, once with antigen in 159 CFA (on day 0) and twice with antigen in IFA (on days 15 and 28) before being 160 scarified on day 32. Blood samples were collected from all rabbits at 0, 28 and 32 days 161 of immunization. Sera were separated and its immunoreactivity was tested using ELISA 162 (see below) against Fasciola antigenic preparations, and the purified 27-kDa antigen. 163
The specificity of the developed sera was tested using ELISA against adult S. mansoni 164 and A. lumbricoides antigenic preparations. Sera of non immunized rabbits were tested 165 in parallel. The highly reactive rabbit sera were then aliqouted and stored at -20 °C until 166
used. 167
Biochemical treatments. To determine some of the target Fasciola antigen biochemical 168 characteristics, samples of the purified 27-kDa antigen were treated with protease and 169
sodium meta-periodate being tested in ELISA, to see if these treatments affected the 170 reactive epitope. A periodate oxidation of purified antigen (25 µg/ml) was carried out 171 overnight with 20 mM sodium meta-periodate at RT and the reaction was then inhibited 172 by adding an equal volume of 130 mM glycerol. In the test with protease, purified 173 antigen was incubated at 37 o C with pepsin (1 mg/ml; Sigma) for 5, 10, 15, or 20 min. shown against ESP or FWAP using the saturated rabbit anti-serum with of the 27-kDa 251 protein (Fig. 1C) . The electro-eluted 27-kDa antigen gave a single polypeptide band 252 when investigated by SDS-PAGE and silver staining, and the purity of the eluted 27-253 kDa polypeptide was confirmed using CZE, only a single peak (5.9 minutes) was 254 observed (Fig. 1D) . A sharp band was observed at 27-kDa in sera from individuals 255 infected with F. gigantica but no reaction was observed in sera of uninfected individuals 256 ( adult worm using normal rabbit serum as a negative control (Fig. 3B) . 268
Detection of the Fasciola circulating antigen in human serum samples using FgCA-269 27 ELISA. From the established calibration curve (Fig. 4A) sample of a parasite free-healthy individual showed a sharp band at 27-kDa and the 296 remaining 3 sera of E. histolytica infected individuals showed no bands in their blots. 297
Moreover, antigen detection rates (% positivity) increased by increasing the severity of 298 infection (expressed as parasite egg count), Table 1 F. gigantica and no specific reaction was observed in sera of uninfected individuals 328 using western blot (unpublished data). 329
In the present study, the target 27-kDa circulating antigen was isolated and purified from 330 serum sample of F. gigantica infected human and a highly reactive IgG antibody was 331 developed in rabbit to the purified 27-kDa antigen. The newly developed IgG antibody 332 identified a polypeptide band of 27-kDa molecular weight in adult worm and E/S 333 antigenic preparations of F. gigantica but did not recognize any target epitopes in the 334
Ascaris and Schistosoma antigenic extracts and its antigenic determinant was located in 335 the gut and tegument of adult F. gigantica worms. Moreover, the target circulating 336
antigen was identified at 27-kDa molecular weight in sera from individuals infected with 337 F. gigantica and no specific reaction was observed in sera of uninfected individuals 338 on October 20, 2017 by guest http://cvi.asm.org/ Downloaded from 14 using western blot and also detected by using ELISA. An inhibition-western blot assay 339 was performed to confirm that the 27-kDa protein isolated from serum is a parasite 340 molecule. Our antigen is similar in molecular weight to a F. gigantica antigen 341 designated FG27 (42,49). The partial biochemical characterization of our purified 342 antigen confirmed its protein moiety. However, further molecular characterization of our 343 27-kDa target antigen including peptide mapping followed by MS amino acid sequence 344 will be performed in collaboration with a well-equipped laboratory to clarify its identity. 345
The identification of the Fasciola antigens in different FWAP, E/S products and in 346 human serum is of crucial importance for reliable diagnosis of active Fasciola infection. 347
Several sensitive and specific methods based on Fasciola antigen detection in serum and 348 stool using specific antibodies were applied to F. hepatica and In the present study, all serum samples showing false negative ELISA results were of 392 light infection (i.e. egg count < 100 epg) except one was of moderated parasite burden 393 (i.e. egg count 100-299 epg), however, the target 27-kDa antigen was identified in all 394 these samples using the more sensitive western blot. This result may support the idea of 395 immune complexes formation in the samples showing false negative ELISA results. 396
Therefore, the absence of the target 27-kDa antigen in 8 sera of our infected individuals 397 using ELISA may be due to undetectable levels of circulating antigen in these serum 398 samples as a result of immune complex formation with host antibodies that tend to 399 decrease the potential rate of circulating antigen (47, 54). Consequently, the developed 400 assay conditions will be optimized to detect 100% of positive sample by using sample 401 pretreatment with a dissociating buffer for immune complexes. The use of specific 402 capturing of the 27-kDa antigen by using specific rabbit IgG polyclonal antibody coating 403 of the solid phase will be also investigated. Moreover, the identification and detection of 404 the target 27-kDa antigen in stool samples will be investigated to overcome the 405 drawback of immune complex formation. 406
The cross reactivity with other parasites represents a major problem in specificity of 407 immunodiagnostic assays like ELISA, especially in endemic areas (13). Moreover, 408 
